Praxis Precision Medicines (PRAX) Cash & Current Investments (2019 - 2026)

Praxis Precision Medicines' Cash & Current Investments history runs 8 years deep, the most recent figure standing at $786.9 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 139.9% year-over-year to $786.9 million; the TTM figure through Mar 2026 stood at $786.9 million (up 139.9% YoY), while the FY2025 annual figure was $599.3 million, up 52.67% from the prior year.
• Cash & Current Investments was $786.9 million for Q1 2026 at Praxis Precision Medicines, up from $599.3 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $786.9 million in Q1 2026 to a low of $56.0 million in Q2 2022.
• Historically, Cash & Current Investments has averaged $249.2 million across 5 years, with a median of $207.4 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Cash & Current Investments plunged 68.14% in 2022, then soared 382.86% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $61.6 million in 2022, then jumped by 31.95% to $81.3 million in 2023, then jumped by 382.86% to $392.6 million in 2024, then jumped by 52.67% to $599.3 million in 2025, then jumped by 31.29% to $786.9 million in 2026.
• The last three Cash & Current Investments figures came in at $786.9 million (Q1 2026), $599.3 million (Q4 2025), and $267.2 million (Q3 2025), per Business Quant data.